On #WorldCOPDDay, we’re recognizing the impact of COPD and the need for more effective options for people living with this condition. According to the Global Initiative for Chronic Obstructive Lung Disease, COPD is one of the leading causes of death worldwide and affects an estimated 391 million people. A single exacerbation can increase the risk of hospitalization or death — a reminder of the significant unmet need for new therapeutics. GB-0895, our anti-TSLP monoclonal antibody, is currently in a Phase 1 clinical trial in adults with #COPD. This study represents the second indication for GB-0895 and builds on our ongoing work in severe asthma. It reflects our hope that a TSLP-targeted antibody with broader anti-inflammatory effects and an extended dosing interval could help address important needs in management of this disease. Learn more about our #AI-engineered pipeline: https://lnkd.in/eEpPjrTF #ProgrammingBiology | #LungHealth